The combined frequency of anti-ACE2 IgM in severe COVID-19 was 18/66 patients (27.2%) compared with 2/52 patients (3.8%) with moderate COVID-19 (OR 9.38, 95% CI 2.38–42.0; P = 0.0009 by Fisher’s exact test; Figure 2A). The gene discussed is ACE2; the disease is COVID-19.